Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study

Mintu P Turakhia, Manisha Desai, Haley Hedlin, Amol Rajmane, Nisha Talati, Todd Ferris, Sumbul Desai, Divya Nag, Mithun Patel, Peter Kowey, John S Rumsfeld, Andrea M Russo, Mellanie True Hills, Christopher B Granger, Kenneth W Mahaffey, Marco V Perez, Mintu P Turakhia, Manisha Desai, Haley Hedlin, Amol Rajmane, Nisha Talati, Todd Ferris, Sumbul Desai, Divya Nag, Mithun Patel, Peter Kowey, John S Rumsfeld, Andrea M Russo, Mellanie True Hills, Christopher B Granger, Kenneth W Mahaffey, Marco V Perez

Abstract

Background: Smartwatch and fitness band wearable consumer electronics can passively measure pulse rate from the wrist using photoplethysmography (PPG). Identification of pulse irregularity or variability from these data has the potential to identify atrial fibrillation or atrial flutter (AF, collectively). The rapidly expanding consumer base of these devices allows for detection of undiagnosed AF at scale.

Methods: The Apple Heart Study is a prospective, single arm pragmatic study that has enrolled 419,093 participants (NCT03335800). The primary objective is to measure the proportion of participants with an irregular pulse detected by the Apple Watch (Apple Inc, Cupertino, CA) with AF on subsequent ambulatory ECG patch monitoring. The secondary objectives are to: 1) characterize the concordance of pulse irregularity notification episodes from the Apple Watch with simultaneously recorded ambulatory ECGs; 2) estimate the rate of initial contact with a health care provider within 3 months after notification of pulse irregularity. The study is conducted virtually, with screening, consent and data collection performed electronically from within an accompanying smartphone app. Study visits are performed by telehealth study physicians via video chat through the app, and ambulatory ECG patches are mailed to the participants.

Conclusions: The results of this trial will provide initial evidence for the ability of a smartwatch algorithm to identify pulse irregularity and variability which may reflect previously unknown AF. The Apple Heart Study will help provide a foundation for how wearable technology can inform the clinical approach to AF identification and screening.

Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1
Figure 1
Study design. Overview of study flow with example tachograms and screenshots. The tachograms are not visualized or provided to the participant, and analyses are run in the background.
Figure 2
Figure 2
Participant study engagement screenshots. Number of days the participant has been in the study and total number of tachograms recorded for that participant as seen within the app on the phone (left) and watch (right).
Figure 3
Figure 3
Cumulative participant enrollment per week based on operational metrics. [1] Study launch with media promotion (Apple press release, App store feature). [2] Waiting room eliminated. All individuals that had been in the waiting room were invited into the study. Enrollment metering ceased. [3] Single recruitment email sent.

References

    1. Benjamin EJ, Virani SS, Callaway CW, et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation 2018;137(12):e67–492.
    1. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64(21):e1–76.
    1. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006. July 11;114(2):119–25.
    1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22(8):983–8.
    1. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005;36(6): 1115–9.
    1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146(12):857–67.
    1. Lin HJ, Wolf PA, Benjamin EJ, et al. Newly diagnosed atrial fibrillation and acute stroke. The Framingham Study. Stroke 1995. September;26(9):1527–30.
    1. Turakhia MP, Shafrin J, Bognar K, et al. Estimated prevalence of undiagnosed atrial fibrillation in the United States. PLoS ONE 2018;13(4), e0195088.
    1. Turakhia MP, Shafrin J, Bognar K, et al. Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States. Am J Cardiol 2015;116(5):733–9.
    1. Xiong Q, Proietti M, Senoo K, et al. Asymptomatic versus symptomatic atrial fibrillation: A systematic review of age/gender differences and cardiovascular outcomes. Int J Cardiol 2015;191:172–7.
    1. King DR, Mehta ND, Gehi AK, et al. Minimally symptomatic atrial fibrillation patients derive significant symptom relief following rate control or rhythm control therapy. J Clin Med Res 2015;7(9):690–3.
    1. Wong JA, Conen D, Van Gelder IC, et al. Progression of device-detected subclinical atrial fibrillation and the risk of heart failure. J Am Coll Cardiol 2018;71(23):2603–11.
    1. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378(5):417–27.
    1. Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 2016;133(17):1637–44.
    1. Freedman B, Camm J, Calkins H, et al. Screening for atrial fibrillation: a report of the AF-SCREEN International Collaboration. Circulation 2017;135(19):1851–67.
    1. Lowres N, Neubeck L, Salkeld G, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 2014;111(6):1167–76.
    1. Turakhia MP, Ullal AJ, Hoang DD, et al. Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). Clin Cardiol 2015;38(5):285–92.
    1. Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: The mSToPS randomized clinical trial. JAMA 2018;320(2):146–55.
    1. Svennberg E, Engdahl J, Al-Khalili F, et al. Mass screening for untreated atrial fibrillation: the STROKESTOP Study. Circulation 2015;131(25):2176–84.
    1. Reiffel JA, Verma A, Kowey PR, et al. Incidence of previously undiagnosed atrial fibrillation using insertable cardiac monitors in a high-risk population: The REVEAL AF study. JAMA Cardiol 2017;2(10):1120–7.
    1. Sanna T, Diener H-C, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370(26): 2478–86.
    1. US Preventive Services Task Force. Screening for atrial fibrillation with electrocardiography: Us preventive services task force recommendation statement. JAMA 2018;320(5):478–84.
    1. Smith A Record shares of Americans now own smartphones, have home broadband [Internet]. Available from: Pew Research Center, 2017.
    1. Lamkin P Smartwatch popularity booms with fitness trackers on the slide. Forbes.[Internet]. Available from: 2018.
    1. Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility of a novel leadless arrhythmia monitoring device. Am J Cardiol 2013;112(4):520–4.
    1. Sun J, Chernick MR, LaBudde RA. A bootstrap test for comparing two variances: simulation of size and power in small samples. J Biopharm Stat 2011;21(6):1079–93.
    1. Tison GH, Sanchez JM, Ballinger B, et al. Passive detection of atrial fibrillation using a commercially available smartwatch. JAMA Cardiol 2018;3(5):409–16.
    1. Califf RM, Sugarman J. Exploring the ethical and regulatory issues in pragmatic clinical trials. Clin Trials 2015;12(5):436–41.

Source: PubMed

3
Prenumerera